MCID: HYP014
MIFTS: 50

Hyperuricemia malady

Categories: Metabolic diseases, Rare diseases

Aliases & Classifications for Hyperuricemia

About this section

Aliases & Descriptions for Hyperuricemia:

Name: Hyperuricemia 11 49 38 13 67
 
Uricacidemia 11

Classifications:



External Ids:

Disease Ontology11 DOID:1920
MeSH38 D033461
NCIt44 C3961

Summaries for Hyperuricemia

About this section
Disease Ontology:11 An acquired metabolic disease that has material basis in an abnormally high level of uric acid in the blood.

MalaCards based summary: Hyperuricemia, also known as uricacidemia, is related to glomerulocystic kidney disease with hyperuricemia and isosthenuria and hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, and has symptoms including cachexia, cyanosis and dyspnea. An important gene associated with Hyperuricemia is UMOD (Uromodulin), and among its related pathways are Uricosurics Pathway, Pharmacodynamics and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs rasburicase and mannitol hexanitrate have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and endothelial, and related mouse phenotypes are muscle and adipose tissue.

Wikipedia:70 Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid,... more...

Related Diseases for Hyperuricemia

About this section

Diseases in the Hyperuricemia family:

Hereditary Hyperuricemia

Diseases related to Hyperuricemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 118)
idRelated DiseaseScoreTop Affiliating Genes
1glomerulocystic kidney disease with hyperuricemia and isosthenuria33.2HPRT1, SLC22A12, SLC2A9, UMOD
2hyperuricemia, pulmonary hypertension, renal failure, and alkalosis12.1
3hereditary hyperuricemia11.8
4autosomal dominant medullary cystic kidney disease with hyperuricemia11.8
5autosomal dominant medullary cystic kidney disease without hyperuricemia11.8
6deafness hyperuricemia neurologic ataxia11.8
7lesch-nyhan syndrome11.7
8nephropathy familial with hyperuricemia11.7
9hprt-related gout11.4
10hyperuricemic nephropathy, familial juvenile 211.4
11nephronophthisis11.2
12hyperuricemic nephropathy, familial juvenile 111.0
13glycogen storage disease ia11.0
14glycogen storage disease ib10.9
15autosomal dominant tubulointerstitial kidney disease, ren-related10.9
16glycogen storage disease ic10.7
17phosphoribosylpyrophosphate synthetase superactivity10.7
18familial juvenile hyperuricemic nephropathy 410.7
19familial juvenile hyperuricaemic nephropathy10.7
20gout10.6
21diarrhea 4, malabsorptive, congenital10.5HPRT1, XDH
22plasma cell neoplasm10.4HPRT1, XDH
23meier-gorlin syndrome 410.4HPRT1, XDH
24repetitive motion disorders10.3INS, REN
25retinitis pigmentosa 6810.3G6PC, INS
26spastic paraplegia, optic atrophy, and neuropathy10.2HPRT1, SLC22A12, SLC2A9
27obesity10.1
28neurilemmoma of the pleura10.1INS, REN
29endotheliitis10.1
30van maldergem syndrome9.9HPRT1, SLC22A12, SLC2A9, XDH
31heart disease9.9
32vipoma9.9INS, REN, UMOD
33subvalvular aortic stenosis9.9HPRT1, INS, SLC22A12, SLC2A9
34casr-related disorders9.9APOB, INS
35arthritis9.9
36atherosclerosis9.9
37liver disease9.9
38lymphoma9.9
39fatty liver disease9.9
40myocardial infarction9.8
41cystinuria9.8
42acute myocardial infarction9.8
43atrial fibrillation9.8
44fetal methyl mercury syndrome9.8APOB, INS
45psoriatic arthritis9.8
46hepatitis9.8
47leukemia9.8
48nephrolithiasis9.8
49athetosis9.8
50cardiovascular disease risk factor )9.8

Graphical network of the top 20 diseases related to Hyperuricemia:



Diseases related to hyperuricemia

Symptoms for Hyperuricemia

About this section

UMLS symptoms related to Hyperuricemia:


cachexia, cyanosis, dyspnea, enuresis, headache, seizures, signs and symptoms, signs and symptoms, digestive, syncope, vertigo, polydipsia, muscle weakness, hot flushes

Drugs & Therapeutics for Hyperuricemia

About this section

Drugs for Hyperuricemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 104)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AllopurinolapprovedPhase 4, Phase 3, Phase 2137315-30-02094
Synonyms:
1,5-Dihydro-4H-pyrazolo(3,4-D)pyrimidin-4-one
1,5-Dihydro-4H-pyrazolo(3,4-D)pyrimidine-4-one
184856-42-6
1H-Pyrazolo(3,4-D)pyrimidin-4-ol
22767-92-6
315-30-0
39464-14-7
4'-Hydroxypyrazolol(3,4-D)pyrimidine
4-HPP
4-Hydroxy-1H-pyrazolo(3,4-D)pyrimidine
4-Hydroxy-3,4-pyrazolopyrimidine
4-Hydroxypyrazolo(3,4-D)pyrimidine
4-Hydroxypyrazolopyrimidine
4-Hydroxypyrazolyl(3,4-D)pyrimidine
4H-Pyrazolo(3,4-D)pyrimidin-4-one
7HP
A 8003
A0907
A8003_SIGMA
AC-019
AC1L1CWL
AC1Q6FWV
AC1Q6GP7
AKOS000267490
AKOS000269759
AL-100
Adenock
Ailural
Ailurial
Allo-Puren
Allohexal
Allohexan
Alloprin
Allopur
Allopurin
Allopurinol
Allopurinol Sodium
Allopurinol(I)
Allopurinolum
Allopurinolum [INN-Latin]
Allorin
Allozym
Allpargin
Allural
Aloprim
Alopurinol
Alopurinol [INN-Spanish]
Aloral
Alositol
Aluline
Anoprolin
Anzief
Apo-Allopurinol
Apulonga
Apurin
Apurol
Atisuril
B. W. 56-158
BB_SC-5394
BIM-0061756.0001
BSPBio_001798
BW 56-158
BW 56158
BW-56-158
Bio-0799
Bleminol
Bloxanth
C5H4N4O
CCRIS 626
CHEBI:40279
CHEBI:495607
CHEMBL1467
CID2094
CPD-9024
CPD000059083
Caplenal
Capurate
Cellidrin
Cosuric
D000493
DB00437
Dabrosin
Dabroson
DivK1c_000685
Dura Al
EINECS 206-250-9
EN000932
EU-0100102
Embarin
Epidropal
Epuric
Foligan
Geapur
Gichtex
Gotax
HMS1920A15
HMS2091G15
HMS502C07
HPP
 
HSDB 3004
Hamarin
Hexanuret
I03-0052
IDI1_000685
Jenapurinol
Jsp005881
KBio1_000685
KBio2_000386
KBio2_002954
KBio2_005522
KBio3_001298
KBioGR_000550
KBioSS_000386
Ketanrift
Ketobun-A
LS-1180
Ledopur
Lopac-A-8003
Lopac0_000102
Lopurin
Lysuron
MLS000069453
MLS001148183
Milurit
Milurite
Miniplanor
MolPort-000-141-383
MolPort-000-870-337
MolPort-004-758-159
MolPort-004-758-166
MolPort-004-758-167
MolPort-004-758-643
Monarch
NCGC00015094-01
NCGC00015094-03
NCGC00015094-06
NCGC00091134-01
NCGC00091134-02
NCGC00091134-03
NCGC00094580-01
NCGC00094580-02
NCIOpen2_001825
NINDS_000685
NSC 101655
NSC 1390
NSC-1390
NSC101655
NSC1390
Nektrohan
Novopurol
Pan Quimica
Prestwick_511
Progout
Pureduct
Purinol
Quimica, Pan
Remid
Riball
Rimapurinol
Roucol
S1630_Selleck
SAM002554884
SMR000059083
SPBio_000056
SPECTRUM1500108
STK378584
STK711106
Sigapurol
Spectrum2_000098
Spectrum3_000289
Spectrum4_000135
Spectrum5_000768
Spectrum_000026
Suspendol
Takanarumin
Tipuric
UNII-63CZ7GJN5I
Urbol
Uribenz
Uricemil
Uridocid
Uriprim
Uripurinol
Uritas
Urobenyl
Urolit
Urosin
Urtias
Urtias 100
Xanthomax
Xanturat
Xanturic
Zygout
Zyloprim
Zyloprim (tn)
Zyloric
allopurinol
nchembio.92-comp3
nchembio732-comp4
2
Olmesartanapproved, investigationalPhase 4126144689-24-7, 144689-63-4158781, 130881
Synonyms:
144689-24-7
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
4-(hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid
4-(hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylic acid
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
AC1L4KLS
Benicar
Benicar HCT
C437965
CHEBI:48416
CHEMBL1516
CID158781
CPD000466337
CS-088
D05246
DE-092
HMS2051K12
 
I14-10085
L001097
LS-181800
MLS000759446
MLS001424016
MolPort-003-666-606
Olmesartan
Olmesartan (USAN/INN)
Olmesartan [USAN]
Olmesartan medoximil
Olmesartan medoxomil
Olmetec
RNH 6270
RNH-6270
SAM001246634
SMR000466337
UNII-8W1IQP3U10
Votum
olmesartan
omesartan
3
Prednisoneapproved, vet_approvedPhase 4, Phase 2, Phase 3135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
4
Rasburicaseapproved, investigationalPhase 4, Phase 3, Phase 225134774-45-1
Synonyms:
Elitek
Fasturtec
 
Urate oxidase
Uricase
rasburicase
5
FebuxostatapprovedPhase 4, Phase 3, Phase 2, Phase 152144060-53-7134018
Synonyms:
111GE013
144060-53-7
2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID
2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid
2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid
2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid
2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
AC-425
AC1L33UC
Adenuric
C16H16N2O3S
CHEBI:45943
CHEBI:747206
CHEMBL1164729
CID134018
D01206
DB03786
 
FT-0081351
Febuxostat
Febuxostat (JAN/USAN/INN)
Febuxostat [USAN]
Febuxostatum
Fébuxostat
LS-173202
MolPort-005-940-740
S1547
S1547_Selleck
TEI
TMX 67
TMX-67
TMX-67, Adenuric, Uloric, Febuxostat
Tei 6720
Tei-6720
UNII-101V0R1N2E
Uloric
6
ProbenecidapprovedPhase 4, Phase 22757-66-94911
Synonyms:
4-((Dipropylamino)sulfonyl)benzoic acid
4-(Di-N-propylsulfamoyl)benzoesaeure
4-(Di-n-propylsulfamoyl)benzoesaeure
4-(Dipropylsulfamoyl)benzoic acid
4-(N,N-Dipropylsulfamoyl)benzoesaeure
4-[(dipropylamino)sulfonyl]benzoic acid
57-66-9
AB00052080
AC-2023
AC1L1J86
AC1Q2XQM
AC1Q2XQN
AI3-50078
AKOS000165123
Apurina
BIDD:GT0626
BIDD:PXR0092
BPBio1_000643
BRD-K95237249-001-05-9
BRN 2815775
BSPBio_000583
BSPBio_002227
Bencid
Benecid
Benemid
Benemid (TN)
Benemide
Benuryl
Biokanol Brand of Probenecid
C07372
C13H19NO4S
CAS-57-66-9
CCRIS 3643
CHEBI:177474
CHEMBL897
CID4911
CPD000058280
Col-BENEMID
Col-Probenecid
ColBenemid (co mponent of)
ColBenemid (component of)
Colbenemid
D00475
D011339
DB01032
DivK1c_000056
EINECS 200-344-3
HMS1569N05
HMS1920J22
HMS2092C03
HMS500C18
HSDB 3387
I01-1905
ICN Brand of Probenecid
IDI1_000056
IDIS Brand of Probenecid
KBio1_000056
KBio2_001314
KBio2_003882
KBio2_006450
KBio3_001727
KBioGR_000971
KBioSS_001314
LS-33
MLS000028496
MLS001076472
Major Brand of Probenecid
Martec Brand of Probenecid
Merck Brand of Probenecid
MolPort-000-145-935
NCGC00016251-01
NCGC00016251-02
NCGC00023829-03
 
NCGC00023829-04
NCGC00023829-05
NCGC00023829-06
NCI-C56097
NINDS_000056
NSC 18786
NSC18786
Ophthalmic Brand of Probenecid
Oprea1_416955
P-(Dipropylsulfamoyl)benzoic acid
P8761_SIGMA
Panuric
Parabenem
Parmed Brand of Probenecid
Polycillin-BRB
Polycillin-PRB
Polycillin-PRB (component of)
Prestwick0_000542
Prestwick1_000542
Prestwick2_000542
Prestwick3_000542
Prestwick_809
Pro-Cid
Probalan
Probampacin
Probecid
Proben
Proben-C
Probenecid (JP15/USP/INN)
Probenecid Acid
Probenecid Major Brand
Probenecid Martec Brand
Probenecid Parmed Brand
Probenecid Weimer
Probenecid Zenith Brand
Probenecid [INN:BAN:JAN]
Probenecid acid
Probenecida
Probenecida [INN-Spanish]
Probenecide
Probenecide [INN-French]
Probenecidum
Probenecidum [INN-Latin]
Probenemid
Probenicid
Probenid
Probexin
Prolongine
Robenecid
SAM002554923
SBB028597
SMR000058280
SPBio_001327
SPBio_002504
SPECTRUM1500502
Spectrum2_001294
Spectrum3_000554
Spectrum4_000486
Spectrum5_001419
Spectrum_000834
Sulprin
Synergid R
Tubophan
UNII-PO572Z7917
Uricosid
Urocid
Valdecasas Brand of Probenecid
WLN: QVR DSWN3&3
Zenith Brand of Probenecid
p-(Dipropylsulfamoyl)benzoic acid
p-(Dipropylsulfamyl)benzoic acid
p-[Dipropylsulfamoyl]benzoic acid
probenecid
probenicid
7
ColchicineapprovedPhase 4, Phase 211164-86-86167, 2833
Synonyms:
(S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide
30512-31-3
5843-86-7
64-86-8
7-alpha-H-Colchicine
7.alpha.H-Colchicine
7alphaH-Colchicine
AC1L1LXO
ACon1_000353
AI3-31149
AKOS001582887
BB_NC-0737
BPBio1_000535
BRD-K00259736-001-06-5
BSPBio_000485
BSPBio_002083
Benzo(a)heptalen-9(5H)-one
C 9754
C07592
C22H25NO6
C3915_SIGMA
C9754_SIGMA
CCRIS 691
CHEBI:27882
CHEMBL107
CID6167
CPD-9785
Colchicin
Colchicin [German]
Colchicina
Colchicina [Italian]
Colchicine (JP15/USP)
Colchicine (TN)
Colchicine [JAN]
Colchicine, (+-)-Isomer
Colchicine, (R)-Isomer
Colchicine, Colchicum autumnale
Colchicinum
Colchineos
Colchisol
Colchysat
Colcin
Colcrys
Colsaloid
Colstat
Condylon
D003078
D00570
DB01394
DB08117
DivK1c_000753
EINECS 200-598-5
EU-0100310
Goutnil
HMS1569I07
HMS1920A08
HMS2091G16
HMS502F15
HSDB 3044
IDI1_000753
KBio1_000753
KBio2_001322
KBio2_003890
 
KBio2_006458
KBio3_001303
KBioGR_000856
KBioSS_001322
Kolkicin
LOC
LS-279
Lopac0_000310
MEGxp0_001879
MLS001055448
MLS001055448-02
MLS001304089
MLS002153786
MPC-004
MolPort-001-742-594
N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)- acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide
N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide
N-Acetyl trimethylcolchicinic acid methylether
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide
NCGC00025125-01
NCGC00025125-02
NCGC00025125-03
NCGC00025125-04
NCGC00025125-05
NCGC00025125-06
NCGC00025125-07
NCGC00025125-11
NCGC00169157-01
NCGC00169157-02
NCGC00169157-03
NCI60_041659
NChemBio.2007.10-comp20
NINDS_000753
NSC 757
NSC757
Prestwick0_000363
Prestwick1_000363
Prestwick2_000363
Prestwick3_000363
Prestwick_695
S2284_Selleck
SDCCGMLS-0066633.P001
SMR000058323
SPBio_000289
SPBio_002406
SPECTRUM1500205
Spectrum2_000075
Spectrum3_000362
Spectrum4_000298
Spectrum5_000787
Spectrum_000842
Tocris-1364
UNII-SML2Y3J35T
UPCMLD-DP065
UPCMLD-DP065:001
WLN: L B677 MV&T&J CO1 DO1 EO1 JMV1 NO1
ZINC00621853
binds to tubulin
colchicine
inhibits microtubular assembly
nchembio853-comp2
spindle poison
8
Omeprazoleapproved, investigational, vet_approvedPhase 433773590-58-64594
Synonyms:
( -)-Omeprazole
(-)-Omeprazole
(S)-(-)-Omeprazole
(S)-Omeprazole
119141-89-8
131959-78-9
172964-80-6
2,3,5-Trimethylpyridine/Omeprazole
2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole
2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole
5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
73590-58-6
AC-401
AC1L1IIJ
AGI-010
AKOS005066653
AULCER
Antra
Antra MUPS
Audazol
Aulcer
Axagon
BIDD:GT0189
BPBio1_000425
BRD-A55962179-001-04-9
BSPBio_000385
Belmazol
Bio-0888
C07324
CAS-73590-58-6
CCRIS 7099
CHEBI:519601
CHEBI:7772
CHEMBL1503
CID4594
CPD000058847
Ceprandal
D00455
DB00338
DB00736
DM-3458
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
Emilok
Epirazole
Erbolin
Esomeprazole
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168-68
H 168/68
H-168/68
H168/68
HMS1528I05
HMS1569D07
HMS2052G17
HMS2090E16
HMS2090F11
HSDB 3575
I06-0705
IDI1_032523
Indurgan
Inhibitron
Inhipump
LS-7629
Lensor
Logastric
Lomac
Losec
Losec, Omesec, Prilosec, Zegerid, Omeprazole
Lucen
MLS000069373
MLS001076112
MLS001424148
Maybridge4_002645
Mepral
Miol
Miracid
MolPort-003-666-741
MolPort-003-807-515
MolPort-003-849-702
Mopral
Morecon
NCGC00016925-01
 
NCGC00016925-02
NCGC00021522-03
NCGC00021522-04
NCGC00021522-05
Nexiam
Nexium
Nexium IV
Nilsec
Nopramin
Nuclosina
O0359
O104_SIGMA
OMEP
OMP
OMZ
Ocid
Olexin
Olit
Omapren
Omebeta
Omebeta 20
Omed
Omegast
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole (JAN/USP/INN)
Omeprazole Pellets
Omeprazole [USAN:INN:BAN:JAN]
Omeprazole delayed-release
Omeprazole magnesium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprazone
Omeprol
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
Ompanyt
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Prazentol
Prazidec
Prazolit
Prestwick0_000493
Prestwick1_000493
Prestwick2_000493
Prestwick3_000493
Prestwick_808
Prilosec
Prilosec (TN)
Prilosec OTC
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
S1389_Selleck
SAM001246900
SAN-15
SMR000058847
SPBio_002306
STK623746
Sanamidol
Secrepina
TL8005099
Tedec Ulceral
UNII-KG60484QX9
UPCMLD-DP075
UPCMLD-DP075:001
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
Victrix
Zefxon
Zegerid
Zepral
Zimor
Zoltum
esomeprazol
omeprazole
9
Naproxenapproved, vet_approvedPhase 425122204-53-11302, 156391
Synonyms:
(+)-(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-(S)-6-Methoxy-α-methyl-2-naphthaleneacetic acid
(+)-(S)-Naproxen
(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionic acid
(+)-2-(Methoxy-2-naphthyl)-propionsaeure
(+)-2-(Methoxy-2-naphthyl)-propionsaeure [German]
(+)-2-(Methoxy-2-naphthyl)-propionsäure
(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(+)-Naproxen
(+)NAPROXEN
(2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid
(S)-()-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-()-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-(+)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-(+)-Naproxen
(S)-2-(6-Methoxy-2-naphthyl)propanoic acid
(S)-2-(6-Methoxy-2-naphthyl)propionic acid
(S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid
(S)-6-Methoxy-alpha-methyl-2-naphthaleneacetic acid
(S)-Naproxen
2-(6-Methoxy-2-naphthyl)propionic acid
2-Naphthaleneacetic acid, 6-methoxy-alpha-methyl-, (+)- (8CI)
22204-53-1
284785_ALDRICH
46482_FLUKA
46482_RIEDEL
65126_FLUKA
AC-1363
AC1L4G3X
AC1Q4ET9
AC1Q4F4H
AC1Q4F4I
ARONIS24306
Acusprain
Aleve
Anaprox
Anax
Anexopen
Apo-Napro-NA
Apo-Naproxen
Apronax
Artagen
Arthrisil
Artrixen
Artroxen
Atiflan
Axer
BIDD:GT0062
BRD-K59197931-001-02-9
BRD-K59197931-236-09-6
BSPBio_002067
Bipronyl
Bonyl
CAS-22204-53-1
CCRIS 5265
CG 3117
CHEBI:7476
CHEMBL154
CID156391
Calosen
Clinosyn
Congex
D-Naproxen
DB08298
DL Naproxen
DL-Naproxen
Danaprox
Daprox
Diocodal
DivK1c_000242
Duk
Dysmenalgit
Dysmenalgit N
EINECS 244-838-7
Ec-Naprosyn
Equiproxen
Equiproxen (Veterinary)
FT-0082415
Flanax Forte
Flexen
Flexipen
Floginax
Fuxen
Genoxen
HMS1920P13
HMS2089N21
HMS2091H12
HMS500M04
HSDB 3369
Headlon
IDI1_000242
InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
KBio1_000242
KBio2_001457
KBio2_004025
KBio2_006593
KBio3_001567
KBioGR_000597
KBioSS_001457
LS-124738
 
Laraflex
Lefaine
Leniartil
Lopac0_000792
M1021
Methoxypropiocin
MolPort-000-145-960
N8280_SIAL
NAPROXEN
NCGC00016759-01
NCGC00021127-01
NCGC00161591-01
NINDS_000242
NPS
Nafasol
Naixan
Nalyxan
Napflam
Napmel
Naposin
Napratec
Naprelan
Napren
Napren E
Naprius
Naprolag
Naprontag
Naprosin
Naprosyn LLE
Naprosyn LLE Forte
Naprosyne
Naproxen
Naproxen Sodium
Naproxen [USAN:BAN:INN:JAN]
Naproxene
Naproxene [INN-French]
Naproxeno
Naproxeno [INN-Spanish]
Naproxenum
Naproxenum [INN-Latin]
Naproxi 250
Naproxi 500
Naproxène
Napxen
Narma
Narocin
Naxen
Naxen F
Naxopren
Naxyn
Naxyn 250
Naxyn 500
Noflam
Novonaprox
Nycopren
Opipramol
Patxen
Prafena
Prestwick0_000791
Prestwick1_000791
Prestwick2_000791
Prestwick_349
Prexan
Priaxen
Pronaxen
Proxen LE
Proxen LLE
RS 3540
RS-3540
Rahsen
Reuxen
Rheumaflex
Roxen
SPBio_000966
SPBio_002861
SPECTRUM1500425
SR-01000075977-3
STOCK1N-50633
Saritilron
Sinartrin
Sinton
Soproxen
Spectrum2_001043
Spectrum3_000514
Spectrum4_000069
Spectrum5_001327
Spectrum_000977
Sutolin
Sutony
TL8003659
Tohexen
Traumox
U-Ritis
UNII-57Y76R9ATQ
UPCMLD-DP001
UPCMLD-DP001:001
Velsay
Veradol
Vinsen
Xenar
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure
d-2-(6'-Methoxy-2'-naphthyl)-propionsaeure [German]
d-2-(6-Methoxy-2-naphthyl)propionic acid
d-Naproxen
10
CanagliflozinapprovedPhase 4107842133-18-0
Synonyms:
 
Canagliflozin anhydrous
11
Uric Acidexperimental, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113369-93-21175
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-Trihydroxypurine
2,6,8-Trioxopurine
2,6,8-Trioxypurine
 
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Lithate
Lithic acid
Purine-2,6,8(1H,3H,9H)-trione
Urate
Uric acid
12insulinPhase 4, Phase 34524
13Insulin, Globin ZincPhase 4, Phase 34523
14Protective AgentsPhase 4, Phase 3, Phase 2, Early Phase 17190
15AntimetabolitesPhase 4, Phase 3, Phase 211774
16Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110627
17AntioxidantsPhase 4, Phase 3, Phase 2, Early Phase 12928
18Peripheral Nervous System AgentsPhase 4, Phase 222776
19
Olmesartan medoxomilPhase 4126144689-63-4130881
Synonyms:
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate
144689-63-4
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester
1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
1H-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
AC-1601
AC1L2Y71
BRD-K78485176-001-02-9
BSPBio_003491
Benevas
Benicar
Benicar (TN)
Benicar, Olmetec,Olmesartan
Berlin-Chemie Brand of Olmesartan Medoxomil
Bio-0071
C097933
CHEMBL1200692
CID130881
CS-866
CS-866DM
CS-866RN
Cs 866
D01204
DB00275
DE-092
Forest Brand of Olmesartan Medoxomil
HMS1922L15
HMS2089K18
 
HMS2093K16
I06-0025
KBio2_002490
KBio2_005058
KBio2_007626
KBio3_002711
KBioGR_001040
KBioSS_002498
KS-1182
L001061
LS-181818
MolPort-003-666-605
MolPort-005-935-047
NCGC00095136-01
NCGC00095136-02
Olmesartan medoximil
Olmesartan medoxomil
Olmesartan medoxomil (JAN/USAN)
Olmetec
Olmetec (TN)
Olvance
S1587_Selleck
SPBio_000431
SPECTRUM1505205
Sankyo Brand of Olmesartan Medoxomil
Spectrum2_000506
Spectrum3_001676
Spectrum4_000740
Spectrum5_001556
Spectrum_001944
UNII-6M97XTV3HD
20Hypoglycemic AgentsPhase 45733
21DiacetylrheinPhase 412
22Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 24295
23AnalgesicsPhase 4, Phase 211287
24Analgesics, Non-NarcoticPhase 4, Phase 26260
25Antimitotic AgentsPhase 4, Phase 25498
26glucocorticoidsPhase 4, Phase 2, Phase 34920
27Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 312767
28
BenzbromaronePhase 4, Phase 1, Phase 253562-84-32333
Synonyms:
(2-Ethyl-3-benzofuranyl)-(3,5-dibrom-4-hydroxyphenyl)keton
(3,5-Dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone
(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone
(3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone
2-Ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran
3, 5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone
3,5-Dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone
3-(3,5-Dibromo-4-hydroxybenzoyl)-2-ethylbenzofuran
3-[3,5-DIBROMO-4-HYDROXYBENZOYL]-2-ETHYLBENZOFURAN
3562-84-3
AC-6162
AC1L1DG0
AL, Benzbromaron
Acifugan
Aliud Brand of Benzbromarone
Azubromaron
B5774_FLUKA
B5774_SIGMA
BPBio1_000549
BRD-K11717138-001-03-0
BRN 0273668
BSPBio_000499
Benzbromaron
Benzbromaron AL
Benzbromaron ratiopharm
Benzbromaron-ratiopharm
Benzbromarone
Benzbromarone (JP15/USAN/INN)
Benzbromarone Aliud Brand
Benzbromarone Heumann Brand
Benzbromarone Sanfer Brand
Benzbromarone [USAN:INN:BAN]
Benzbromarone ratiopharm Brand
Benzbromarone(USAN)
Benzbromaronratiopharm
Benzbromaronum
Benzbromaronum [INN-Latin]
Benzobromarona
Benzobromarona [INN-Spanish]
Besuric
C17H12Br2O3
CAS-3562-84-3
CHEBI:3023
CHEMBL388590
CID2333
CPD000058310
D001553
D01056
Desuric
EINECS 222-630-7
Exurate
FT-0083530
HMS1569I21
HMS2052K05
 
HMS2093J04
Harolan
Heumann Brand of Benzbromarone
Hipurik
I06-1261
KETONE, 3,5-DIBROMO-4-HYDROXYPHENYL 2-ETHYL-3-BENZOFURANYL
Ketone, 3,5-dibromo-4-hydroxyphenyl 2-ethyl-3-benzofuranyl
L 2214
L 2214-Labaz
L-2214
L2214
L2214-Labaz
LS-87131
MJ 10061
MLS000028522
MLS000737128
MLS001074105
MLS001424143
Methanone, (3
Minuric
MolPort-002-622-240
NCGC00013895
NCGC00013895-02
NCGC00013895-03
NCGC00022066-04
NCI60_041884
NCI85433
NCIStruc1_001498
NCIStruc2_001681
NSC 85433
NSC-85433
NSC85433
Narcaricin
Normurat
Oprea1_140235
Prestwick0_000370
Prestwick1_000370
Prestwick2_000370
Prestwick3_000370
Prestwick_709
SAM001246877
SBB057006
SMR000058310
SPBio_002420
Sanfer Brand of Benzbromarone
Sanofi Winthrop Brand of Benzbromarone
UNII-4POG0RL69O
UNM000001228903
Uricovac
Urinorm
Uroleap
Uroleap (TN)
ZINC00608205
benzbromarone
ratiopharm Brand of Benzbromarone
29
Angiotensin IIPhase 4116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
30Renal AgentsPhase 4, Phase 1, Phase 2732
31Antihypertensive AgentsPhase 4, Phase 3, Phase 24095
32HormonesPhase 4, Phase 2, Phase 313979
33Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 310355
34AngiotensinogenPhase 41161
35Angiotensin Receptor AntagonistsPhase 41173
36Angiotensin II Type 1 Receptor BlockersPhase 41078
37Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 35407
38Hormone AntagonistsPhase 4, Phase 2, Phase 312778
39Antiprotozoal AgentsPhase 41986
40Anti-Infective AgentsPhase 421402
41Antiparasitic AgentsPhase 42127
42
Proton pump inhibitorsPhase 41080
Synonyms:
 
PPIs
43Anti-Ulcer AgentsPhase 41767
44Gastrointestinal AgentsPhase 48109
45AntacidsPhase 41767
46Cyclooxygenase InhibitorsPhase 42778
47AnthocyanidinNutraceuticalPhase 478
48
ProcyanidinNutraceuticalPhase 4284852-22-6147299
Synonyms:
 
Catechin-(4alpha->8)-epicatechin
Procyanidin B4
49ProanthocyanidinNutraceuticalPhase 428
50
ChlorthalidoneapprovedPhase 36377-36-12732
Synonyms:
(+-)-Chlorthalidone
(+-)-Hygroton
1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
1-keto-3-(3'-Sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(1-Hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-Hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine
3-(4'-chloro-3'-Sulfamoylphenyl)-3-hydroxyphthalimidine
3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
5-22-07-00602 (Beilstein Handbook Reference)
77-36-1
A3836/0162845
AB00051946
AC-11367
AC1L1ECB
AC1Q558X
BPBio1_000487
BRD-A26384407-001-05-3
BRN 0312295
BSPBio_000441
BSPBio_002017
C14H11ClN2O4S
C2775_FLUKA
C2775_SIGMA
CHEBI:3654
CHEMBL1055
CID2732
CPD000058635
Chlorothalidone
Chlorphthalidolone
Chlorphthalidone
Chlortalidone
Chlortalidone (JAN/INN)
Chlortalidonum
Chlortalidonum [INN-Latin]
Chlorthalidon
Chlorthalidone
Chlorthalidone (USP)
Chlorthalidone [USAN:INN:BAN]
Clodronic Acid
Clortalidona
Clortalidona [INN-Spanish]
Clortalidone
Clortalidone [DCIT]
D00272
D002752
DB00310
DivK1c_000731
EINECS 201-022-5
Famolin
G 33182
G-33182
HMS1569G03
HMS1920M09
 
HMS2091E12
HMS502E13
HSDB 3035
Higroton
Hydro-Long
Hygroton
Hygroton (TN)
I06-0208
IDI1_000731
Igroton
Isoren
KBio1_000731
KBio2_000626
KBio2_003194
KBio2_005762
KBio3_001237
KBioGR_001574
KBioSS_000626
LS-31408
MLS000069531
MolPort-002-736-049
NCGC00094616-01
NCGC00094616-02
NCGC00094616-03
NCGC00094616-04
NINDS_000731
NSC 69200
NSC69200
Natriuran
Oksodolin (oxodolin)
Oradil
Oxodolin
Oxodoline
Phthalamodine
Phthalamudine
Prestwick0_000351
Prestwick1_000351
Prestwick2_000351
Prestwick3_000351
Prestwick_759
Racemic chlorthalidone
Renon
SAM002589983
SMR000058635
SPBio_000058
SPBio_002362
SPECTRUM1500187
ST088141
STK686335
Saluretin
Spectrum2_000099
Spectrum3_000349
Spectrum4_000957
Spectrum5_000743
Spectrum_000146
Tenoretic
Thalitone
Thalitone (TN)
UNII-Q0MQD1073Q
Urolin
Zambesil
chlorthalidone

Interventional clinical trials:

(show top 50)    (show all 117)
idNameStatusNCT IDPhase
1Prednisone for Heart Failure Patients With HyperuricemiaCompletedNCT00919243Phase 4
2Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis SyndromeCompletedNCT00563771Phase 4
3Rasburicase in Tumor Lysis SyndromeCompletedNCT00302653Phase 4
4Treatment of Hyperuricemia in Patients With Heart FailureCompletedNCT00422318Phase 4
5Zurig (Febuxostat) 40mg Efficacy and Safety TrialCompletedNCT02600780Phase 4
6Effects of Hyperuricemia Reversal on Features of the Metabolic SyndromeCompletedNCT01654276Phase 4
7Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy PatientsCompletedNCT00186940Phase 4
8Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor MalignancyCompletedNCT00230217Phase 4
9Allopurinol in Chronic Heart FailureCompletedNCT00997542Phase 4
10Drug Interaction Study of Olmesartan in Healthy Chinese VolunteersCompletedNCT01907373Phase 4
11Allopurinol Outcome StudyCompletedNCT01391325Phase 4
12Weight Loss Improves Renal HemodynamicsCompletedNCT01356394Phase 4
13Fasturtec TLS Treatment / ProphylysisCompletedNCT00651911Phase 4
14Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate LevelsCompletedNCT02060552Phase 4
15Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by AnthocyanidinesRecruitingNCT02797028Phase 4
16The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and DynamicsRecruitingNCT02956278Phase 4
17Virtual Gout ClinicActive, not recruitingNCT02790463Phase 4
18Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With GoutActive, not recruitingNCT02500641Phase 4
19Pharmacogenetics of SGLT2 InhibitorsEnrolling by invitationNCT02462421Phase 4
20the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and HyperuricemiaNot yet recruitingNCT02279342Phase 4
21Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated HyperuricemiaCompletedNCT00921375Phase 3
22Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis SyndromeCompletedNCT00230178Phase 3
23Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade LymphomaCompletedNCT00199043Phase 3
24Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic GoutCompletedNCT00325195Phase 3
25Efficacy and Safety of Oral Febuxostat in Participants With GoutCompletedNCT00430248Phase 3
26Uric Acid and Hypertension in African AmericansCompletedNCT00241839Phase 3
27Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic GoutCompletedNCT01356498Phase 3
28Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010CompletedNCT00175019Phase 3
29Prednisone for Heart Failure Patients With HyperuricemiaRecruitingNCT02129764Phase 2, Phase 3
30Study of FYU-981 in Hyperuricemia With or Without GoutRecruitingNCT03006445Phase 3
31Long-term Prednisone Use for End-stage Heart FailureRecruitingNCT02282683Phase 2, Phase 3
32UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood PressureRecruitingNCT02038179Phase 2, Phase 3
33The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive PatientsRecruitingNCT02563405Phase 2, Phase 3
34Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic PatientsRecruitingNCT02533648Phase 3
35Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComorbiditiesActive, not recruitingNCT01101035Phase 3
36Rasburicase (Fasturtec) Registration TrialTerminatedNCT00607152Phase 3
37Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and GoutUnknown statusNCT01519687Phase 2
38A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.Unknown statusNCT00208000Phase 2
39Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout PatientsUnknown statusNCT02290210Phase 2
40Hyperuricemia on Hypertension and Metabolic SyndromeCompletedNCT01157936Phase 2
41Study of Tranilast Alone or in Combination With Febuxostat in Patients With HyperuricemiaCompletedNCT00995618Phase 2
42Study of Tranilast Alone or in Combination With Allopurinol in Subjects With HyperuricemiaCompletedNCT01052987Phase 2
43Study of FYU-981 in Hyperuricemia With or Without GoutCompletedNCT02344862Phase 2
44Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic HyperuricemiaCompletedNCT02078219Phase 2
45A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia PatientsCompletedNCT02317861Phase 1, Phase 2
46Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With GoutCompletedNCT01336686Phase 2
47Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout PatientsCompletedNCT01416402Phase 2
48A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic GoutCompletedNCT00741442Phase 2
49Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutCompletedNCT02252835Phase 2
50Rasburicase for HyperuricemiaCompletedNCT00290992Phase 2

Search NIH Clinical Center for Hyperuricemia

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: hyperuricemia

Genetic Tests for Hyperuricemia

About this section

Anatomical Context for Hyperuricemia

About this section

MalaCards organs/tissues related to Hyperuricemia:

35
Kidney, Heart, Endothelial, Liver, Skeletal muscle, Bone, Thyroid

Animal Models for Hyperuricemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Hyperuricemia:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053699.1APOB, HPRT1, INS, PFKM, REN, XDH
2MP:00053759.0ABCG2, ADRB3, INS, SLC2A9, UMOD, XDH
3MP:00053709.0ABCG2, APOB, G6PC, HPRT1, INS, SLC2A9
4MP:00053868.1ADRB3, G6PC, HPRT1, INS, PFKM, REN
5MP:00053878.0ABCG2, APOB, HPRT1, INS, PFKM, REN
6MP:00053787.8ADRB3, APOB, G6PC, HPRT1, INS, REN
7MP:00053677.6ABCG2, G6PC, HPRT1, INS, REN, SLC22A12
8MP:00053767.0ABCG2, ADRB3, APOB, G6PC, HPRT1, INS

Publications for Hyperuricemia

About this section

Articles related to Hyperuricemia:

(show top 50)    (show all 680)
idTitleAuthorsYear
1
Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population. (28027534)
2017
2
Hyperuricemia Protects Against Low Bone Mineral Density, Osteoporosis and Fractures: A Systematic Review And Meta-Analysis. (27636234)
2016
3
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout. (27980008)
2016
4
Hyperuricemia is associated with increased hospitalization risk and healthcare costs: Evidence from an administrative database in Italy. (27555289)
2016
5
Detrimental role of hyperuricemia on the cardio-reno-vascular system. (26414733)
2015
6
Assessment of a possible link between hyperhomocysteinemia and hyperuricemia. (25646870)
2015
7
Hyperuricemia and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. (26545082)
2015
8
Effects of hyperuricemia on renal function in pediatric renal transplant recipients. (25894164)
2015
9
Hyperuricemia is independently associated with increased risk of atrial fibrillation: A meta-analysis of cohort studies. (25777070)
2015
10
Nonalcoholic Fatty Liver Disease and Hyperuricemia: A Close Relation with Hepatic Insulin Resistance after Nicotinic Acid Treatment? (25350520)
2014
11
Definition of hyperuricemia and gouty conditions. (24419750)
2014
12
The ABCG2 Polymorphism rs2725220 Is Associated with Hyperuricemia in the Korean Population. (25705163)
2014
13
Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice. (25451835)
2014
14
Prevalence and determinants of hyperuricemia in type 2 diabetes mellitus patients with central obesity in Guangdong Province in China. (24231020)
2013
15
Beneficial effect of rutin on oxonate-induced hyperuricemia and renal dysfunction in mice. (23942050)
2013
16
Hyperuricemia is associated with hypertension, obesity, and albuminuria in children with chronic kidney disease. (22809658)
2013
17
Mediterranean diet and risk of hyperuricemia in elderly participants at high cardiovascular risk. (23599357)
2013
18
Hyperuricemia and non-dipping blood pressure. (24348063)
2013
19
Prednisone in Uric Acid lowering in Symptomatic Heart Failure Patients With Hyperuricemia (PUSH-PATH) study. (23395281)
2013
20
Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: a retrospective study. (22705193)
2012
21
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. (21654265)
2011
22
Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. (21783292)
2011
23
Lack of association between dietary fructose and hyperuricemia risk in adults. (20193069)
2010
24
Gout and hyperuricemia. (21229813)
2010
25
A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. (19701676)
2009
26
Outcome of directly observed treatment short course (DOTS) in a case of pulmonary tuberculosis with hyperuricemia. (19810595)
2009
27
Gout. Novel therapies for treatment of gout and hyperuricemia. (19664185)
2009
28
Gout Study Group: update on hyperuricemia and gout. (19559637)
2009
29
Relationship between hyperuricemia and metabolic syndrome]. (18409529)
2008
30
Drug discovery for hyperuricemia. (23496132)
2007
31
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout. (17396159)
2007
32
Prevalence of the metabolic syndrome in individuals with hyperuricemia. (17466656)
2007
33
Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. (16385546)
2006
34
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. (16448895)
2006
35
Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children. (16911488)
2006
36
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. (16820043)
2006
37
Hyperuricemia and associated diseases. (16716880)
2006
38
Purine metabolites in gout and asymptomatic hyperuricemia: analysis by HPLC-electrospray tandem mass spectrometry. (16120958)
2005
39
The effect of alcoholic beverage type on hyperuricemia in Japanese male office workers. (15762093)
2005
40
Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia. (15170929)
2004
41
Diuretic-induced hyperuricemia does not decrease cardiovascular risk. (15201561)
2004
42
Hyperuricemia and reticulocytopenia in association with autoimmune hemolytic anemia in two children. (15539377)
2004
43
Pathogenesis of hyperuricemia: recent advances. (12010614)
2002
44
Hyperuricemia and renal function. (11353569)
2001
45
Latent overproductive hyperuricemia increases in patients during the intermittent phase of gouty arthritis under long-term antihyperuricemic treatment. (24383630)
2000
46
Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. (10413068)
1999
47
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. (10571797)
1999
48
Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. (9369411)
1997
49
Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. (8637443)
1996
50
Hyperuricemia]. (8009701)
1994

Variations for Hyperuricemia

About this section

Expression for genes affiliated with Hyperuricemia

About this section
Search GEO for disease gene expression data for Hyperuricemia.

Pathways for genes affiliated with Hyperuricemia

About this section

GO Terms for genes affiliated with Hyperuricemia

About this section

Cellular components related to Hyperuricemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1endosome lumenGO:003190410.0APOB, INS
2apical plasma membraneGO:00163247.9ABCG2, PFKM, SLC17A3, SLC22A12, SLC2A9, UMOD

Biological processes related to Hyperuricemia according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1glycogen catabolic processGO:000598010.1G6PC, PFKM
2urate transportGO:001574710.0SLC17A3, SLC22A12
3glucose-6-phosphate transportGO:00157609.9G6PC, SLC17A3
4drug transmembrane transportGO:00068559.8ABCG2, SLC17A3
5glucose transportGO:00157589.6G6PC, INS, SLC2A9
6phosphate ion transportGO:00068179.6SLC17A1, SLC17A3
7sodium-dependent phosphate transportGO:00443419.6SLC17A1, SLC17A3
8phosphate ion transmembrane transportGO:00354359.6SLC17A1, SLC17A3
9response to organic substanceGO:00100339.5APOB, REN, UMOD
10glucose homeostasisGO:00425939.4G6PC, INS, PFKM
11organic acid transmembrane transportGO:19038259.3SLC17A3, SLC22A12, SLC2A9
12urate metabolic processGO:00464158.1ABCG2, G6PC, SLC17A1, SLC17A3, SLC22A12, SLC2A9

Molecular functions related to Hyperuricemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor receptor bindingGO:000515910.3INS, REN
2sodium-dependent phosphate transmembrane transporter activityGO:00153219.7SLC17A1, SLC17A3
3sodium:phosphate symporter activityGO:00054369.7SLC17A1, SLC17A3
4urate transmembrane transporter activityGO:00151439.4SLC17A3, SLC22A12, SLC2A9
5protein homodimerization activityGO:00428038.7ABCG2, ADRB3, HPRT1, PFKM, XDH

Sources for Hyperuricemia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet